OnabotulinumtoxinA, Nerve Stimulation Devices, Mirabegron, and Anticholinergics Versus Best Supportive Care for Overactive Bladder: An Updated US Cost-Effectiveness Analysis Meeting Abstract

publication date

  • July 1, 2022

webpage

published in

keywords

  • Anticholinergics
  • Best supportive care
  • Cost-effectiveness
  • Mirabegron
  • Nerve stimulation devices
  • OnabotulinumtoxinA

start page

  • S42

end page

  • S43

volume

  • 214